Journal
CURRENT FUNGAL INFECTION REPORTS
Volume 10, Issue 2, Pages 51-61Publisher
SPRINGER
DOI: 10.1007/s12281-016-0255-4
Keywords
Posaconazole; Therapeutic drug monitoring; Pharmacokinetics; Pharmacodynamics; Invasive fungal infection; Invasive aspergillosis; Prophylaxis; Dried blood spot; Mucormycosis; Scedosporium infections; Fusarium infections
Categories
Ask authors/readers for more resources
Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available